Namrata Vijayvergia, MD
Medical Oncology · Philadelphia, PANPI 1871741025
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $69,159 of the $93,244 with a category attached, or 74.2%. It is spread thinly across 20 manufacturers, the largest accounting for just 18.8%. 2025 is the largest year on record at $37,868, more than ten times the $113 reported in 2019. Among medical oncology clinicians in PA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 91 payments — averaging $1024.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$18K
- Exelixis Inc.$15K
- Taiho Oncology, Inc.$9K
- Boehringer Ingelheim$9K
- Lexicon Pharmaceuticals, Inc.$7K
- Jazz Pharmaceuticals Inc.$6K
- plus $29K from 14 others
Across 17 payments — averaging $17,960 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- E.r. Squibb & Sons, L.L.C.$165K
- Merck$127K
- Incyte Corporation$5K
- Novartis$4K
- Jazz Pharmaceuticals Inc.$4K
What the payments were for
- Consulting fees$69,15974%
- Speaking & faculty fees$17,94219%
- Travel & lodging$4,3535%
- Food & beverage$1,7902%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 6 | $17,500 |
| Exelixis Inc. | 28 | $14,878 |
| Taiho Oncology, Inc. | 4 | $9,410 |
| Boehringer Ingelheim | 3 | $9,103 |
| Lexicon Pharmaceuticals, Inc. | 9 | $7,087 |
| Jazz Pharmaceuticals Inc. | 1 | $5,768 |
| AstraZeneca | 8 | $5,296 |
| Tersera Therapeutics LLC | 5 | $5,083 |
| Array Biopharma Inc | 6 | $4,810 |
| Advanced Accelerator Applications | 1 | $3,275 |
| Daiichi Sankyo Inc. | 2 | $2,740 |
| Gilead | 2 | $2,578 |
| Novartis | 3 | $1,661 |
| Ipsen Biopharmaceuticals, Inc | 1 | $1,400 |
| Regeneron | 5 | $1,262 |
| Novocure Inc. | 1 | $600 |
| Beigene, Ltd. | 1 | $600 |
| Eisai Inc. | 1 | $113 |
| Regeneron Healthcare Solutions, Inc. | 3 | $63 |
| Astellas Pharma US Inc | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$93,244 in reported general payments places this provider in the 90th percentile of 238 medical oncology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Everolimus | 17 | $101,505 |
| CreonLipase/Protease/Amylase | 11 | $13,782 |
| Prochlorperazine Maleate | 39 | $413 |
| Pantoprazole Sodium | 11 | $256 |
| Ondansetron Hcl | 35 | $242 |
| Dexamethasone | 14 | $149 |
| Lidocaine-PrilocaineLidocaine/Prilocaine | 17 | $134 |
| Ondansetron OdtOndansetron | 11 | $119 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Philadelphia
- Carl JunePhiladelphia$9M
- Shayma KazmiPhiladelphia$619K
- Marcia BrosePhiladelphia$260K
- Adam CohenPhiladelphia$239K
- Daniel HallerPhiladelphia$227K
- Edith MitchellPhiladelphia$220K
- Elizabeth PlimackPhiladelphia$190K
- Alexander PerlPhiladelphia$176K
- Martin EdelmanPhiladelphia$157K
- Jean-Pierre IssaPhiladelphia$147K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.